Practical considerations on non-vitamin K oral anticoagulants in patients with high body weight

References (5)

1. Güler E, Babur Güler G, Demir GG, Hatipoğlu S. A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough? Anatol J Cardiol 2015: 1020-9
2. Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol 2011; 155: 137-49
3. Undas A, Pasierski T, Windyga J, Crowther M. Practical aspects of new oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn 2014; 124: 124-35
4. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Mea-suring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Antico-agulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013 Jan 24. Epub of ahead of print
5. Zalewski J, Rychlak R, Góralczyk T, Undas A. Rivaroxaban concen-tration in patients with deep vein thrombosis who reported throm-bus progression or minor hemorrhagic complications: first Polish experience. Pol Arch Med Wewn 2014; 124: 553-5.